Dr. Adi Goldenzweig is Co-Founder and CTO at Scala Biodesign, a Tel Aviv-based biotech company transforming protein development through AI-driven computational design for therapeutic and industrial applications.

Dr. Goldenzweig conducted her doctoral research in Prof. Sarel Fleishman's laboratory at the Weizmann Institute of Science, where she co-developed the PROSS algorithm, a state-of-the-art protein redesign method adopted by over 80 research labs worldwide.

Her research directly produced real-world impact, including a redesigned malaria vaccine candidate that advanced to Phase II clinical trials in West Africa and optimized wood-degrading enzymes for biofuel production.

At Scala Biodesign, Dr. Goldenzweig leads the computational technology stack underpinning ScalaOS, an enterprise-grade platform that integrates physics-based modeling, evolutionary analysis, and LLM-based AI to optimize proteins in a single design cycle.

Scala's platform has been validated by 50+ research labs and over 150 scientific publications, and ScalaOS has onboarded nine of the world's top 20 pharmaceutical companies within its first eight months of commercial availability.